TARGET THERAPY FOR mRCC – SCHEMES & RESULTS | ||||
---|---|---|---|---|
Scheme/Drug | Line of Treatment | Molecular Target | Mean PFS (Months) | Mean OS(Months) |
Sunitinib1,2 | First | mTKI | 11 | 26,4 |
Temsirolimus1 | First | mTOR | 1,9 | 10,9 |
Pazopanib1 | First | mTKI | 11,8 | 22,9 |
Sorafenib1 | Second | mTKI | 5,5 | 17,8 |
Bevacizumab + IFNα1 | Second | VEGF-A | 8,5 | 18,3 |
Axitinib1 | Second | mTKI | 6,7 | 20,1 |
Everolimus1 | Second | mTOR | 4 | 14,8 |
Nivolumab1 | Second | PD-1 | 4,6 | 25 |
Cabozatinib1,2 | Second | mTKI | 7,4 | 21,4 |
Lenvatinb + Everolimus1 | Second | mTKI/mTOR | 14,6 | NR |
Nivolumab + Ipilimumab2 | Second | PD-1/PD-L1 | 12,6 | NR |
Atezolizumab + Bevacizumab2 | Second | PD-L1/VEGF-A | 11,2 | NR |